Please use this identifier to cite or link to this item:
Title: Experience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin.
Austin Authors: McMahon, L P;Dawborn, J K
Affiliation: Department of Medicine, Austin Hospital, Heidelberg, Victoria.
Issue Date: 16-May-1990
Publication information: American Journal of Nephrology; 10(5): 404-8
Abstract: Twelve stable haemodialysis patients were divided into two groups and given recombinant human erythropoietin (r-HuEPO) for 14 weeks either intravenously (i.v.) or subcutaneously (s.c.). Dosage was 25 units/kg either thrice (i.v.) or twice (s.c.) per week for 7 weeks, and then 50 units/kg for a further 7 weeks. Response to s.c. therapy was comparable to i.v. despite a 33% lower weekly dosage, and was significant at both 7 (i.v.: 1.1 +/- 0.3, mean +/- SEM, p = 0.02; s.c.: 0.8 +/- 0.3 g/dl, p = 0.03) and 14 weeks (i.v.: 2.8 +/- 0.5, p = 0.003; s.c.: 2.6 +/- 0.6 g/dl, p = 0.009). A correlation was observed between response to r-HuEPO and initial ferritin levels (r = 0.63, p = 0.04). One patient required an increase in antihypertensive medication and there was one arteriovenous fistula thrombosis. Results suggest that overall s.c. therapy is as effective as i.v. therapy, and that a good response with few side effects can be obtained using relatively low doses of r-HuEPO.
Gov't Doc #: 2080791
Type: Journal Article
Subjects: Anemia.drug therapy.etiology
Drug Administration Schedule
Erythropoietin.administration & dosage.therapeutic use
Injections, Intravenous
Injections, Subcutaneous
Kidney Failure, Chronic.complications.therapy
Recombinant Proteins.administration & dosage.therapeutic use
Renal Dialysis
Appears in Collections:Journal articles

Show full item record

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.